Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali M Harandi

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Immunology Letters|March 9, 2005
Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNAJan Holmgren, Jenni Adamsson, Fabienne Anjuère, et al.
Science Translational Medicine|April 14, 2017
A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and AfricaAngela Huttner, Christophe Combescure, Stéphane Grillet, et al.
Scientific Reports|December 14, 2016
Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine AdjuvantsThorunn A Olafsdottir, Madelene Lindqvist, Intawat Nookaew, et al.
Cell Reports|November 30, 2022
Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cellsNimitha R Mathew, Jayalal K Jayanthan, Ilya V Smirnov, et al.
Cell Reports|June 23, 2021
Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cellsNimitha R Mathew, Jayalal K Jayanthan, Ilya V Smirnov, et al.
The Journal of Infection|August 9, 2024
Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, GabonAyodele Alabi, Kossiwa Kokou, Saidou Mahmoudou, et al.
Frontiers in Immunology|March 19, 2026
Correction: Long non-coding RNAs in response to Ebola virus vaccine-induced immunityIzabela Mamede, Thomaz Luschër-Dias, Isabelle Franco Moscardini, et al.
Frontiers in Immunology|February 26, 2026
Long non-coding RNAs in response to Ebola virus vaccine-induced immunityIzabela Mamede, Thomaz Luschër-Dias, Isabelle Franco Moscardini, et al.
Nature Biotechnology|August 28, 2012
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigensFrank Wegmann, Kate H Gartlan, Ali M Harandi, et al.
Plos Neglected Tropical Diseases|June 26, 2008
Immunity against HIV/AIDS, malaria, and tuberculosis during co-infections with neglected infectious diseases: recommendations for the European Union research prioritiesDiana Boraschi, Markos Abebe Alemayehu, Abraham Aseffa, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Immunology Letters|March 9, 2005
Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNAJan Holmgren, Jenni Adamsson, Fabienne Anjuère, et al.
Science Translational Medicine|April 14, 2017
A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and AfricaAngela Huttner, Christophe Combescure, Stéphane Grillet, et al.
Scientific Reports|December 14, 2016
Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine AdjuvantsThorunn A Olafsdottir, Madelene Lindqvist, Intawat Nookaew, et al.
Cell Reports|November 30, 2022
Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cellsNimitha R Mathew, Jayalal K Jayanthan, Ilya V Smirnov, et al.
Cell Reports|June 23, 2021
Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cellsNimitha R Mathew, Jayalal K Jayanthan, Ilya V Smirnov, et al.
The Journal of Infection|August 9, 2024
Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, GabonAyodele Alabi, Kossiwa Kokou, Saidou Mahmoudou, et al.
Frontiers in Immunology|March 19, 2026
Correction: Long non-coding RNAs in response to Ebola virus vaccine-induced immunityIzabela Mamede, Thomaz Luschër-Dias, Isabelle Franco Moscardini, et al.
Frontiers in Immunology|February 26, 2026
Long non-coding RNAs in response to Ebola virus vaccine-induced immunityIzabela Mamede, Thomaz Luschër-Dias, Isabelle Franco Moscardini, et al.
Nature Biotechnology|August 28, 2012
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigensFrank Wegmann, Kate H Gartlan, Ali M Harandi, et al.
Plos Neglected Tropical Diseases|June 26, 2008
Immunity against HIV/AIDS, malaria, and tuberculosis during co-infections with neglected infectious diseases: recommendations for the European Union research prioritiesDiana Boraschi, Markos Abebe Alemayehu, Abraham Aseffa, et al.
Pageof 8